Sertraline in the treatment of panic disorder: A multi-site, double-blind, placebo-controlled, fixed-dose investigation
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background: This study compared the efficacy and safety of sertraline to placebo in treating panic disorder. Method: 178 out-patients with panic disorder who exhibited at least four panic attacks during the four weeks prior to screening and three during the two weeks of lead-in were randomly assigned to 12 weeks of double-blind treatment with sertraline (50, 100 or 200 mg) or placebo. Results: Sertraline was superior to placebo in reducing the number of panic attacks, situational attacks, unexpected attacks, limited symptom attacks, and time spent worrying (all P < 0.01) and the Hamilton Anxiety Scale (P < 0.05), although Clinical Global Impression (Improvement) did not significantly differentiate groups at 12 weeks and at end-point. No serious adverse events were associated with sertraline. No dose relationship was found for adverse events; overall drop-out rates were not different for sertraline or placebo, although more sertraline-treated subjects discontinued for adverse events, typically early in the study. Only dry mouth and ejaculation failure (primarily ejaculation delay) were associated significantly with sertraline. Conclusions Sertraline was effective and safe in reducing panic attacks. Higher doses were no more effective than the 50 mg dose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Multicenter Collaborative Panic Disorder Severity Scale
Shear, M. K., Brown, T. A., Barlow, D. H., Money, R., Sholomskas, D. E., Woods, S. W., Gorman, J. M., & Papp, L. A. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.11.1571 · Cited by 1,001
Clark, D. M., Salkovskis, P. M., Hackmann, A., Middleton, H., Anastasiades, P., & Gelder, M. (1994) · British Journal of Psychiatry · doi:10.1192/bjp.164.6.759 · Cited by 673
Paroxetine in the Treatment of Panic Disorder a Randomised, Double-Blind, Placebo-Controlled Study
Oehrberg, S., Christiansen, P. E., Behnke, K., Borup, A. L., Severin, B., Soegaard, J., Calberg, H., Judge, R., Ohrstrom, J. K., & Manniche, P. M. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.167.3.374 · Cited by 261
Cassano, G. B., Toni, C., Petracca, A., Deltito, J., Benkert, O., Curtis, G., Hippius, H., Maier, W., Shera, D., & Klerman, G. (1994) · European Neuropsychopharmacology · doi:10.1016/0924-977x(94)90314-x · Cited by 23
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Brady, K., Pearlstein, T., Asnis, G. M., Baker, D., Rothbaum, B., Sikes, C. R., & Farfel, G. M. (2000) · JAMA · doi:10.1001/jama.283.14.1837 · Cited by 690
Effects of SSRIs on Sexual Function: A Critical Review
Rosen, R. C., Lane, R. M., & Menza, M. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199902000-00013 · Cited by 650
Davidson, J. R. T., Rothbaum, B. O., van der Kolk, B. A., Sikes, C. R., & Farfel, G. M. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.5.485 · Cited by 470
Mitte, K. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2005.05.003 · Cited by 396
Reliability and validity of the Panic Disorder Severity Scale: replication and extension
Shear, M. K., Rucci, P., Williams, J., Frank, E., Grochocinski, V., Vander Bilt, J., Houck, P., & Wang, T. (2001) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(01)00028-0 · Cited by 360
Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction
Montgomery, S. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(01)00313-5 · Cited by 205
Rief, W., Nestoriuc, Y., von Lilienfeld-Toal, A., Dogan, I., Schreiber, F., Hofmann, S. G., Barsky, A. J., & Avorn, J. (2009) · Drug Safety · doi:10.2165/11316580-000000000-00000 · Cited by 202
Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety
Kent, J. M., Coplan, J. D., & Gorman, J. M. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00210-8 · Cited by 196
Selective serotonin reuptake inhibitors in affective disorders — I. Basic pharmacology
Goodnick, P. J., & Goldstein, B. J. (1998) · Journal of Psychopharmacology · doi:10.1177/0269881198012003021 · Cited by 183
Anxiety disorders: a comprehensive review of pharmacotherapies
Hoffman, E. J., & Mathew, S. J. (2008) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20041 · Cited by 149
Roest, A. M., de Jonge, P., Williams, C. D., de Vries, Y. A., Schoevers, R. A., & Turner, E. H. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.15 · Cited by 101
Minority inclusion in randomized clinical trials of panic disorder
Mendoza, D. B., Williams, M. T., Chapman, L. K., & Powers, M. (2012) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2012.02.011 · Cited by 70
“Two studies (Londborg et al., 1998; Mauret, Hofmann, & Rosenfield, 2010) did indicate that there were a majority of White participants in the study (<90”
Risks and benefits of medications for panic disorder: A comparison of SSRIs and benzodiazepines
Quagliato, L. A., Freire, R. C., & Nardi, A. E. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1429403 · Cited by 62
“Dry mouth, dyspepsia, headache [10,14,15], tremor, asthenia, drowsiness, and insomnia [14,20] were also reported as side effects of SSRIs in PD.”
BackgroundMichelson, D., Allgulander, C., Dantendorfer, K., Knezevic, A., Maierhofer, D., Micev, V., Paunovic, V. R., Timotijevic, I., Sarkar, N., Skoglund, L., et al. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.6.514 · Cited by 62
Treatment-Resistant Panic Disorder
Bandelow, B., & Rüther, E. (2004) · CNS Spectrums · doi:10.1017/s1092852900022379 · Cited by 57
Antipanic Drug Modulation Of 35% CO2 Hyperreactivity and Short-Term Treatment Outcome
Perna, G., Bertani, A., Caldirola, D., Gabriele, A., Cocchi, S., & Bellodi, L. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200206000-00011 · Cited by 48
Simon, N. M., Otto, M. W., Worthington, J. J., Hoge, E. A., Thompson, E. H., LeBeau, R. T., Moshier, S. J., Zalta, A. K., & Pollack, M. H. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04485blu · Cited by 45
Dannon, P. N., Iancu, I., & Grunhaus, L. (2002) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.421 · Cited by 41
“E-mail: dannon@attglobal.net Judge, 1997), sertraline (Londborg et al., 1998), citalopram (Lepola et al., 1998), and fluoxetine (Gorman et al., 1987)—have become the first-line treatment for panic disorder.”
BackgroundPharmacotherapy of panic disorder
Pull, C. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s1224 · Cited by 32
Mar, P. L., Raj, V., Black, B. K., Biaggioni, I., Shibao, C. A., Paranjape, S. Y., Dupont, W. D., Robertson, D., & Raj, S. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113512911 · Cited by 24
“…several psychiatric conditions, including major depressive disorder (Keller et al., 1998), obsessive compulsive disorder (Kronig et al., 1999), panic disorder (Londborg et al., 1998), post-traumatic stress disorder (Davidson et al., 2001), and premenstrual dysphoric disorder (Yonkers et al., 1997).”
BackgroundSafer, D. J. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000564 · Cited by 19
Metadata
- Authors
- Londborg, P. D., Wolkow, R., Smith, W. T., Duboff, E., England, D., Ferguson, J., Rosenthal, M., & Weise, C.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 1998-07
- Volume
- 173
- Issue
- 1
- Pages
- 54-60
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2042791643
- Cited by
- 141
- References
- 5
- FWCI
- 23.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.